The global Pharma Grade Synthetic Camphor Market Sales is anticipated to be worth US$ 532.0 million by the end of 2028, according to the company’s most recent analysis. The Pharma Grade Synthetic Camphor market research anticipates enormous growth potential, with an average year-on-year growth rate of 4.2% expected through 2028. The growing need for topical …
Author Archives: Editor AM
Vein Finder Market Share 2022 to 2028 | By Christie Medical, Osang Healthcare, AccuVein, Teleflex, TransLite
The global Vein Finder Market Size is anticipated to be worth roughly US$ 46.7 million in 2022 and approximately US$ 86.8 million by 2028. During the forecast period, the market is expected to increase at a CAGR of 10.9%. Innovative Vein Finder technology is sweeping the medical device business, with sophisticated Vein Finders and cutting-edge …
Psoriatic Arthritis (PsA) Treatment Market is likely to register CAGR of 7.1% through 2028
The global Psoriatic Arthritis (PsA) Treatment Market Size is anticipated to approach US$ 10.3 billion by 2022. The market is estimated to reach US$ 15.6 billion by 2028, with a 7.1% CAGR. The Psoriatic Arthritis (PsA) Treatment Market is expected to develop at a 7.1% CAGR between 2022 and 2028, up from a 6.7% CAGR …
Generic Oncology Drugs Market is likely to register CAGR of 6% through 2028
The global Generic Oncology Drugs Market Demand is predicted to increase at a 6% CAGR between 2022 and 2028, reaching more than US$ 34.8 billion by the end of 2028. Individuals’ increasing proclivity to smoke and tobacco intake is the leading cause of cancer. Sedentary lifestyle, genetic causes, virus infections, carcinogens, and a high consumption …
Continue reading “Generic Oncology Drugs Market is likely to register CAGR of 6% through 2028”
Global Ringworm Treatment Market to reach US$ 13.91 billion by 2033, Topical Drugs to account for 64% of all Treatment Approaches: FMI Study
The global Ringworm Treatment Market is anticipated to reach US$ 13.91 billion in 2033 and expand at a CAGR of 5.2% between 2023 and 2033, according to Future Market Insights. The increasing prevalence of skin diseases and the high incidence rates of ringworm are contributing reasons to the market for ringworm treatments. Additionally, as bacterial …
Hematopoietic Stem Cell Transplantation Market is projected to reaching US$ 15 Billion by the year 2033 at a decent CAGR of 8%
The global Hematopoietic Stem Cell Transplantation Market is worth US$ 7 Billion as of now and expected to reach US$ 15 Billion by the year 2033 at a CAGR of 8% between 2023 and 2033. With rise in geriatric population, the probability of contracting hematopoietic stem cell abounds. This factor is expected to keep the …
Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Is Expected to Register Growth at 5.2% CAGR through 2033- FMI Study
The global Eosinophilic Granulomatosis With Polyangiitis Treatment Market is currently valued at US$ 173.8 Million in 2023 and is anticipated to expand at a CAGR of 5.2%. Owing to the technological advances in healthcare the market is likely to propel to US$ 288.5 Million by 2033. The growing occurrences of churg strauss syndrome and other allergic reactions and …
Chronic Refractory Cough Treatment Market | Aurobindo Pharma Ltd, Mylan N.V., GSK Plc., Hikma Pharmaceuticals Plc | By 2033
The Chronic Refractory Cough Treatment Market is anticipated to be worth US$ 9.2 billion in 2023 and US$ 17.1 billion by 2033, growing at a CAGR of 6.39%. The market for treatments for refractory chronic cough is driven by the rising prevalence of refractory chronic cough worldwide. The size of the market would increase, enabling pharmaceutical companies …
Diamond-Blackfan Anemia (DBAAASE) Syndrome Therapeutics Market is projected to exhibit a CAGR of 4.2% from 2023 to 2033, a valuation of US$ 7.29 billion
At a compound annual growth rate (CAGR) of 4.2% from 2023 to 2033, the Diamond-Blackfan Anemia (DBAAASE) Syndrome Therapeutics Market is expected to surpass an amazing US$ 4.8 billion in 2023. By 2033, the market for therapeutics for Diamond-Blackfan Anaemia (DBAAASE) Syndrome is anticipated to be worth US$7.29 billion. Due to the fact that 90% …
Chronic Granulomatous Disease (CGD) Management Market | Bellicum Pharmaceuticals, Inc, Pfizer Inc, Hoffmann-La Roche Ltd, Novartis AG | By 2033
According to Future Market Insights, the Chronic Granulomatous Disease (CGD) Management Market is anticipated to expand at a rate of 4.9% CAGR between 2023 and 2033. The management of Chronic Granulomatous Disease (CGD) is anticipated to reach a market valuation of US$2.11 billion by the year 2033. Due to a number of factors, including the …